Royal London Asset Management LTD Alkermes Plc. Transaction History

Royal London Asset Management LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 05, 2020	SELL	$17.29 - $21.74 $947,664 - $1.19 Million	-54,810 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$19.51 - $24.28 $1.07 Million - $1.33 Million	54,810 New	54,810 $1.07 Million
Q2 2019 Jul 31, 2019	SELL	$21.47 - $37.33 $1.37 Million - $2.38 Million	-63,649 Closed	0 $0
Q4 2018 Jan 29, 2019	SELL	$27.94 - $44.61 $1.27 Million - $2.03 Million	-45,541 Reduced 41.71%	63,649 $1.81 Million
Q3 2018 Nov 08, 2018	BUY	$38.6 - $46.12 $1.76 Million - $2.1 Million	45,541 Added 71.55%	109,190 $0

Q2 2018 Sep 19, 2018	BUY	$40.56 - $51.36 $2.58 Million - $3.27 Million	63,649 New	63,649 $2.62 Million

357

180M

522K

463K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $3.97B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Royal London Asset Management LTD, based on Form 13F filings with the SEC.

Stay updated on Royal London Asset Management LTD with notifications on news.